63763-79-1

Basic information

• Product Name: PYRIDINE, 2-(BROMOMETHYL)-6-CHLORO-
• Synonyms: PYRIDINE, 2-(BROMOMETHYL)-6-CHLORO-;6-CHLORO-2-BROMOMETHYLPYRIDINE;2-(Bromomethyl)-6-Chloropyridine
• CAS NO: 63763-79-1
• Molecular Formula: C₆H₅BrClN
• Molecular Weight: 206.47
• Mol File: 63763-79-1.mol

Chemical Properties

• Boiling Point: 241.089°C at 760 mmHg
• Flash Point: 99.607°C
• Appearance: /
• Density: 1.664g/cm³
• Vapor Pressure: 0.057mmHg at 25°C
• Refractive Index: 1.59
• Storage Temp.: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
• PKA: -1.24±0.10(Predicted)
• CAS DataBase Reference: PYRIDINE, 2-(BROMOMETHYL)-6-CHLORO-(CAS DataBase Reference)
• NIST Chemistry Reference: PYRIDINE, 2-(BROMOMETHYL)-6-CHLORO-(63763-79-1)
• EPA Substance Registry System: PYRIDINE, 2-(BROMOMETHYL)-6-CHLORO-(63763-79-1)

Safety Data

• Hazardous Substances Data: 63763-79-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
PYRIDINE, 2-(BROMOMETHYL)-6-CHLOROis used as a key intermediate in the synthesis of heteroaryl amine derivatives. These derivatives are crucial for the development of diacylglycerol acyltransferase 2 (DGAT2) inhibitors, which play a significant role in the treatment of various metabolic disorders, including obesity and type 2 diabetes. PYRIDINE, 2-(BROMOMETHYL)-6-CHLORO-'s unique structure allows for the formation of these therapeutically relevant molecules, contributing to the advancement of pharmaceutical research and drug development.

InChI:InChI=1/C6H5BrClN/c7-4-5-2-1-3-6(8)9-5/h1-3H,4H2

Upstream product

• 4684-94-0 6-chloropicolinic acid 
• 6636-55-1 methyl 6-chloropicolinate 
• 33674-97-4 6-chloro-2-pyridinemethanol 
• 18368-63-3 6-chloro-2-picoline 

Downstream Products

• 1191102-67-6 ethyl 7-[(6-chloropyridin-2-yl)methoxy]-5-[4-(methylsulfonyl)phenoxy]-1H-indole-2-carboxylate 
• 872104-47-7 9,10-bis{[6-(diphenylphosphanyl)-2-pyridylmethyl]propylaminomethyl}anthracene 

Relevant articles and documents

Tuning the conversion of cyclohexane into cyclohexanol/one by molecular dioxygen, protons and reducing agents at a single non-porphyrinic iron centre and chemical versatility of the tris(2-pyridylmethyl)amine TPAFe IICl2 complex in mild oxidation chemistry

We report that the oxygen sensitivity of some Fe(ii) complexes with tripodal ligands can be used, with benefit, in the oxidation of cyclohexane under mild conditions. Depending on the solvent, two very different reaction pathways are involved, which share the coordination of O2 to the metal as the common initial step. We have synthesized a series of α-chlorinated tripods in the tris(2-pyridylmethyl)amine series Cl nTPA (n = 1-3) and fully characterized the corresponding FeX 2 complexes (X = Cl, CF3SO3). The single-crystal X-ray structure analyses of the FeCl2 complexes are reported. In CH3CN, the FeCl2 complexes react smoothly with O2, whereas the Fe(CF3SO3)2 complexes are non-sensitive. In CH3CN, the reaction of the oxygen-sensitive ClnTPAFeCl2 (n = 0-3) with O2, acetic acid and zinc amalgam, in the presence of cyclohexane, affords a mixture of cyclohexanol/one in an ≈ ol/one ratio of 3.1 and a selectivity of the C3°/C2° in the adamantane conversion that is consistent with a metal-oxo based oxidation. Limited efficiency (≈ 2 TON) was observed for the parent TPAFeCl2 complex and Cl1TPAFeCl2, whereas both other complexes turned out to be poorly active. The TPAFeCl2 complex was used to address mechanistic questions: when the reaction was carried out in pyridine, the ol/one ratio shifted to 0.15 while efficiency was improved by 7-fold. In pyridine and in the presence of a spin trap (DMPO), the radical-based character of the reaction was definitely established, by contrast with acetonitrile, where no oxygenated radicals were detected. Thus, the reactivity differences arise from involvement of two distinct active species. The dichotomous radical/biomimetic pathway is discussed to interpret these results.

POLY HETEROCYCLIC CONJUGATES AND THEIR PHARMACEUTICAL USES

Compounds of Formula (I) shown below and a pharmaceutical composition containing one of the compounds: Each of the variables is defined herein. Also disclosed is a method of treating a condition associated with uncontrolled cell growth with a compound of Formula (I).

4H- [1, 2, 4] TRIAZOLO [5, 1 -B] PYRIMIDIN-7 -ONE DERIVATIVES AS CCR2B RECEPTOR ANTAGONISTS

The present invention relates to novel compounds for use in the compositions, to processes for their preparation, to intermediates useful in their preparation and to their use as therapeutic agents. The present invention also relates to pharmaceutical com

BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF GLYTL MEDIATED DISORDERS

The present invention relates to benzoxazinone derivatives, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in treating disorders mediated by GlyT1, including neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder.

ANTIVIRAL PHOSPHINATE COMPOUNDS

The invention is related to anti-viral phosphinate compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

Generation and intermodular additions of pyridylmethyl radicals

2-, 3-, or 4-Pyridylmethyl radicals can be made to add to nonactivated alkenes to give a variety of otherwise inaccessible pyridine derivatives. Bicyclic structures can be obtained by combining the radical addition with ionic ring-closure steps. Georg Thieme Verlag Stuttgart.

Molecular modification of anpirtoline, a non-opioid centrally acting analgesic

Molecular modification of anpirtoline (2a) is described. Several methods of preparation of 4-[(3-chlorophenyl)sulfanyl]-1-methylpiperidine (3a) and its demethylation led to the deazaanpirtoline (3c). Nucleophilic substitution of piperidine-4-thiole with 2-chloro-4-nitropyridine, 2,4-dichloro-6-methylpyridine, and 3,6-dichloropyridazine led to 2-chloro-4-(piperidin-4-ylsulfanyl)pyridine (6), 4-chloro-6-methyl-2-(piperidin-4-ylsulfanyl)pyridine (7), and 3-chloro-6-(piperidin-4-ylsulfanyl)pyridazine (8), respectively. 2-Chloro-6-(pyridin-4-ylsulfanyl)-pyridine (10) and 4-[(2-chloropyridin-6-yl)sulfanyl]quinoline (11) were obtained from sodium 2-chloropyridine-6-thiolate. Homoanpirtoline analogs with methylene group inserted between the pyridine moiety and the sulfur atom (compound 12b) as well as between the sulfur atom and the piperidine ring (compound 13b) were also prepared.